Medication overuse headache (MOH) places both a physical and emotional burden on a patient.

MOH occurs as a result of frequent or excessive use of medications for the acute treatment of headaches or migraine.

Despite acute and prophylactic treatment options, there remains a complex subset of patients who require additional therapies due to insufficient response, or failure to respond.

In complex-to-manage patients, newer calcitonin gene-related peptide (CGRP) pathway monoclonal antibody (mAb) therapies, such as eptinezumab, can be considered.